ARID1A and neoplasm: In this experiment, early initiation of VX-970 treatment also dramatically slowed the growth of ARID1A−/− tumours (P=0.015, ANOVA), but did not impair ARID1A+/+ xenografts (P=0.63, ANOVA, Fig. 3e,f).